Image
illustration
Venture Capital Regulatory & Product Launch

MRM HEALTH Receives CTA Approval for Phase 1b/2a Trial with MH002 in Ulcerative Colitis

Tuesday 28 September, 2021
Body

MRM Health have received regulatory approval from the Federal Agency for Medicines and Health Products (FAMHP) in Belgium to start a Phase 1b/2a trial with the novel next-generation optimized consortium therapy, MH002, in patients with mild-to-moderate ulcerative colitis (UC). MH002 is the first rationally-designed consortium therapy, in which key disease-driving mechanisms guide therapeutic microbial strain selection, to enter clinical studies in patients.

Content